The U.S. rig count saw a marginal increase this week, yet remains significantly below last year's levels as crude production dips and completions activity sends conflicting signals.
Financial services firm Lazard (LAZ) reported better-than-expected fourth-quarter results, driven by record advisory fees and robust asset growth, signaling resilience in a challenging market.
Analyst sell ratings are rare on Wall Street, making them noteworthy when they appear. We examine one such case where pessimism may have gone too far, creating a potential opportunity, alongside two stocks where the cautious outlook appears justified.
Analysts have pinned high hopes on several names, but a closer look reveals a more nuanced picture. We examine one company likely to justify the optimism and two where significant risks may be overshadowing the bullish price targets.
KeyBanc Capital Markets has upgraded LivaNova PLC (LIVN) from Sector Weight to Overweight, setting an $81 price target. The move reflects a broader positive shift in analyst sentiment towards the medical technology sector as valuation premiums ease.
Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
Goldman Sachs and Evercore ISI analysts have raised price targets for GE HealthCare Technologies (GEHC), citing a projected market recovery and strong capital expenditure trends by 2026. The medical devices firm is highlighted as a top hedge fund pick.
DexCom Inc. (DXCM) has released preliminary Q4 figures that exceeded expectations and provided robust long-term guidance, reinforcing its position as a favored pick among analysts and hedge funds in the medical devices sector.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
Stablecoin rewards and the Clarity Act widen the divide between crypto and TradFi, according to people who spoke with the WSJ.
Weekly unemployment filings in New York state rose last week, contrasting with a slight national decline and highlighting regional economic disparities.
Allegro MicroSystems (ALGM) reported strong fourth-quarter results, with revenue surging 29% year-over-year to $229.2 million, surpassing analyst expectations. The chip designer's growth was fueled by record data center sales and robust demand in automotive, particularly for electric vehicles and ADAS.
Fueled by surging global demand for its Hoka and Ugg brands, Deckers Outdoor Corp. posted a robust third-quarter performance that surpassed expectations, driving its stock price up sharply and assuaging recent Wall Street concerns over growth sustainability.
Cavco Industries reports robust fiscal Q2 2026 earnings, with revenue up 9.7% year-over-year, driven by double-digit shipment growth in Northern U.S. markets. The company successfully managed a slowdown in the Southeast through operational adjustments and highlighted a significant turnaround in its financial services segment.
Nelnet (NNI) reaffirms its commitment to shareholders with a steady dividend, backed by strong historical revenue growth and share buybacks. Yet, a closer look reveals a complex valuation picture, with contrasting signals from its P/E ratio and discounted cash flow model, leaving analysts divided on the stock's true worth.
Navios Maritime Partners (NMM) has delivered impressive multi-year returns, leaving investors to question if its current valuation still presents an opportunity. With a diversified fleet and strong fundamentals, we examine the bull case and the risks ahead.
SLB has won significant five-year contracts from Petroleum Development Oman for the giant Block-6 field. The deals mandate local wellhead manufacturing and deploy advanced recovery technologies, anchoring SLB's long-term service role and supporting Omani job creation.
